Replimune

Replimune

Yahoo Finance • 25 days ago

Replimune to Present at the Cantor Global Healthcare Conference 2026

WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune m... Full story

Yahoo Finance • 2 months ago

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading... Full story

Yahoo Finance • 2 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entit... Full story

Yahoo Finance • 2 months ago

REPL INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm 

ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statemen... Full story

Yahoo Finance • 2 months ago

Replimune gains accelerated approval of Tudriqev for cutaneous melanoma

[Dermoscopic image of malignant melanoma skin tumor] Izzet Esmece/iStock via Getty Images * The US FDA has granted accelerated approval to Replimune's (REPL [https://seekingalpha.com/symbol/REPL]) gene therapy Tudriqev (vusolimogene ode... Full story

Yahoo Finance • 2 months ago

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL).  Such investors are advised to contact Danielle Peyton at n... Full story

Yahoo Finance • 2 months ago

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile... Full story

Yahoo Finance • 2 months ago

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Quick Read Easing Iran tensions, strong tech earnings, and a 5% oil price drop drove the Nasdaq up 2% and S&P 500 up 1.5% Monday. Deutsche Bank upgraded PLTR to Buy with a $200 target, while DZ Bank cut AAPL to Hold with a $310 target. Up... Full story

Yahoo Finance • 2 months ago

Top Midday Gainers

Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.The commit... Full story

Yahoo Finance • 2 months ago

Securities Fraud Investigation Into Replimune Group Inc. (REPL) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, July 31, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL)... Full story

Yahoo Finance • 2 months ago

Biotech Stocks Facing FDA Decision In August 2026

(RTTNews) - As we head into August, it's time for our monthly roundup of the upcoming FDA decisions that could move biotech stocks. The August regulatory calendar spans a wide range of indications - from the ultra-rare Fibrodysplasia Ossi... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more

Check out the companies making the biggest moves premarket: Replimune Group — Shares were up over 130% for the clinical-stage biotechnology company after a Food and Drug Administration advisory panel voted in favor of the company's RP1 dru... Full story

Yahoo Finance • 2 months ago

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today's meeting o... Full story

Yahoo Finance • 2 months ago

REPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The investigation concerns whether the Company... Full story

Yahoo Finance • 3 months ago

Signs of Economic Resilience Boost Stocks

The S&P 500 Index ($SPX) (SPY) today is up +0.34%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.22%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.97%.  September E-mini S&P futures (ESU26) are up +0.26%, and September E-mini... Full story

Yahoo Finance • 3 months ago

Stock Indexes Supported by Strong Demand for Technology Stocks

The S&P 500 Index ($SPX) (SPY) today is up +0.08%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.50%.  September E-mini S&P futures (ESU26) are up +0.09%, and September E-mini... Full story

Yahoo Finance • 3 months ago

Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.19%.  September E-mini S&P futures (ESU26) fell -0.34%, and... Full story

Yahoo Finance • 4 months ago

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2... Full story

Yahoo Finance • 4 months ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival... Full story